Clinical trial

Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors

NCT07704658

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2026-03-04

PhasePHASE4

Study timeline

Study start (actual)2026-03-04Date precision: day

Registry last updated2026-08-10

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

NSCLC (Non-small Cell Lung Cancer)unresolved

Thyroid Cancerunresolved

Solid Tumor Malignanciesunresolved

Advanced Malignanciesunresolved

Interventions

PralsetinibDRUG · verified · RxNorm: pralsetinib

CYP3A4, CYP2C8, and CYP2C9 substrates, and hormonal contraceptiveDRUG

Sponsors & collaborators

Rigel Pharmaceuticalslead sponsor

Mapped research locations

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07704658 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.